Robin Clark to Opioid-Related Disorders
This is a "connection" page, showing publications Robin Clark has written about Opioid-Related Disorders.
Connection Strength
1.279
-
Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. J Subst Abuse Treat. 2015 Oct; 57:75-80.
Score: 0.294
-
Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014 Dec; 49(6):1964-79.
Score: 0.278
-
Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med. 2013 Sep 23; 173(17):1571-2.
Score: 0.263
-
Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011 Aug; 30(8):1425-33.
Score: 0.227
-
Romo E, Ulbricht CM, Clark RE, Lapane KL. Correlates of specialty substance use treatment among adults with opioid use disorders. Addict Behav. 2018 11; 86:96-103.
Score: 0.090
-
Baxter JD, Clark RE, Samnaliev M, Aweh G, O'Connell E. Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program. Subst Abus. 2015; 36(2):174-82.
Score: 0.072
-
Baxter JD, Clark RE, Samnaliev M, Leung GY, Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. J Subst Abuse Treat. 2011 Jul; 41(1):88-96.
Score: 0.055